Scientific instrument and service provider Thermo Fisher Scientific (MA, USA) has acquired technological solutions company Phitonex Inc. (NC, USA), developers of a spectral dye platform for high-resolution biology applications.
Termed ‘Phiton’, the platform offers an innovative tool for the analysis of single cells in high-resolution. Phiton acts as a structure that can maintain a higher number of fluorescent dyes. It enables the rapid creation of numerous dye labels, minimized cross-excitation, and reduced spectral spillover. This in turn increases the number of protein and cell populations that can be identified in a single cytometry experiment. The goal of Phiton is to speed up cell therapy, immuno-oncology and immunology research, and development.
Peter Silverster, senior vice president and president of life sciences solutions at Thermo Fisher Scientific, stated:
“Phitonex’s platform is a natural extension of Thermo Fisher’s existing tools for protein and cell analysis applications. Combining this new technology with our existing portfolio and expertise in this space will unlock the Phiton platform’s great potential and deliver unparalleled flow cytometry performance so our customers gain more valuable insights from a single cell and expedite discovery.”
Thermo Fisher provides scientific instrumentation, software, reagents and consumables, and services to healthcare and life sciences industries as well as laboratories in academic, government, and industry.
more recommended stories
Kaempferol: A Breakthrough in Allergy ManagementKaempferol, a dietary flavonoid found in.
Early Milk Cereal Drinks May Spur Infant Weight GainNew research published in Acta Paediatrica.
TaVNS: A Breakthrough for Chronic Insomnia TreatmentA recent study conducted by the.
First-of-Its-Kind Gene-Edited Pig Kidney: Towana’s New LifeSurgeons at NYU Langone Health have.
Just-in-Time Training Improves Success & Patient SafetyA study published in The BMJ.
ChatGPT Excels in Medical Summaries, Lacks Field-Specific RelevanceIn a recent study published in.
Study finds automated decision minimizes high-risk medicine combinations in ICU patientsA multicenter study coordinated by Amsterdam.
Study Discovers Connection Between Omicron Infection and Brain Structure Changes in MenA recent study in the JAMA.
Advancing COPD Prognosis: Deep Learning ModelsResearchers conducted a meta-analysis in a.
4 in 1 Test for Swine Flu, COVID-19, RSV, and InfluenzaIn the United Kingdom, the first.
Leave a Comment